Clinical Rheumatology

, 27:1417

High-titer antichromatin antibody is associated with proliferative class IV of lupus nephritis

  • J. F. Carvalho
  • V. S. T. Viana
  • E. F. Borba
  • A. P. do Nascimento
  • E. P. Leon
  • L. A. Testagrossa
  • R. T. Barros
  • E. Bonfá
Original Article

Abstract

The antichromatin antibody (aCT) has been described as a useful marker for lupus nephropathy. The relevance of its nephritogenic potential may be appropriately evaluated in the context of renal histopathology. Therefore, the present study investigated the relationship of aCT with a particular histopathologic class of lupus nephritis (LN). Seventy-eight consecutive patients with systemic lupus erythematosus (ACR criteria) and active nephritis who underwent renal biopsy from 1999 to 2004 and with available frozen serum sample obtained at the time of biopsy were selected. aCT was measured by ELISA, and anti-dsDNA was measured by indirect immunofluorescence (IIF) and by ELISA. All renal biopsies were revised in a blinded manner by the same expert renal pathologist. Charts were extensively reviewed for demographic and renal features obtained at the time of biopsy. The prevalence of aCT (≥20 U) was 59% with a mean titer of 74.3 ± 38.7U. Both aCT-positive and aCT-negative groups of patients had similar age, gender distribution, duration of lupus, and duration of renal disease. Anti-dsDNA was detected by IIF in 29.5% and by ELISA in 42.3% of the patients. Concomitant presence of both antibodies was observed in 63% (29/46) [anti-dsDNA by ELISA] and 45.6% (21/46) [anti-dsDNA by IIF] of the patients. Lower serum levels of C3 (73% vs. 40%, P= 0.0058) and C4 (82% vs. 46.7%, P= 0.0021) were more commonly observed in aCT ≥ 20 U patients compared to the aCT-negative group. It is important to note that the use of a higher cut-off value (≥40 U) for aCT test revealed a predominance of class IV LN (58% vs. 33%, P= 0.039) in aCT ≥ 40 U compared to aCT < 40 U group. The mean levels of proteinuria, serum albumin, and creatinine were markedly altered but were comparable in both groups (P ≥ 0.05). One fourth (26.3%) of the 19 patients with class IV LN and aCT ≥ 40 U had no detectable anti-dsDNA (ELISA). These data suggest that high-titer aCT seems to be a valuable biomarker for proliferative class IV of LN.

Keywords

Antichromatin antibody Anti-dsDNA Antinucleosome antibody Autoantibody Lupus nephritis Systemic lupus erythematosus 

References

  1. 1.
    Kotzin BL (1996) Systemic lupus erythematosus. Cell 85:303–306PubMedCrossRefGoogle Scholar
  2. 2.
    Koffler D, Schur PH, Kunkel HG (1967) Immunological studies concerning the nephritis of systemic lupus erythematosus. J Exp Med 126:607–624PubMedCrossRefGoogle Scholar
  3. 3.
    Tan EM (1989) Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 44:93–151PubMedCrossRefGoogle Scholar
  4. 4.
    Koffler D, Carr R, Agnello V, Thoburn R, Kunkel HG (1971) Antibodies to polynucleotides in human sera: antigenic specificity and relation to disease. J Exp Med 134:294–312PubMedCrossRefGoogle Scholar
  5. 5.
    Foster MH, Cizman B, Madaio MP (1993) Nephritogenic autoantibodies in systemic lupus erythematosus: immunochemical properties, mechanisms of immune deposition, and genetic origins. Lab Invest 69:494–507PubMedGoogle Scholar
  6. 6.
    Reichlin M, Wolfson-Reichlin M (2003) Correlations of anti-dsDNA and anti-ribosomal P autoantibodies with lupus nephritis. Clin Immunol 108:69–72PubMedCrossRefGoogle Scholar
  7. 7.
    Uwatoko S, Mannik M (1988) Low-molecular weight C1q-binding immunoglobulin G in patients with systemic lupus erythematosus consists of autoantibodies to the collagen-like region of C1q. J Clin Invest 82:816–824PubMedCrossRefGoogle Scholar
  8. 8.
    Renaudineau Y, Croquefer S, Jousse S, Renaudineau E et al (2006) Association of alpha-actinin-binding anti-double-stranded DNA antibodies with lupus nephritis. Arthritis Rheum 54:2523–2532PubMedCrossRefGoogle Scholar
  9. 9.
    Cervera R, Viñas O, Ramos-Casals M, Font J et al (2003) Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rheum Dis 62:431–434PubMedCrossRefGoogle Scholar
  10. 10.
    Kalaaji M, Fenton KA, Mortensen ES, Olsen R et al (2007) Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int 71:664–672PubMedCrossRefGoogle Scholar
  11. 11.
    Sigal L (2007) Basic science for the clinician 42: handling the corpses: apoptosis, necrosis, nucleosomes and (quite possibly) the immunopathogenesis of SLE. J Clin Rheumatol 13:44–48PubMedCrossRefGoogle Scholar
  12. 12.
    Burlingame RW, Cervera R (2002) Anti-chromatin (anti-nucleosome) autoantibodies. Autoimmun Rev 1:321–328PubMedCrossRefGoogle Scholar
  13. 13.
    Amoura Z, Koutouzov A, Chabre H, Cacoub P et al (2000) Presence of antinucleosome antibodies in a restricted set of connective tissue diseases. Arthritis Rheum 43:76–84PubMedCrossRefGoogle Scholar
  14. 14.
    Min DJ, Kim SJ, Park SH, Seo YI et al (2002) Antinucleosome antibody: significance in lupus patients lacking anti-double-stranded DNA antibody. Clin Exp Rheumatol 20:13–18PubMedGoogle Scholar
  15. 15.
    Amoura Z, Chabre H, Koutouzov S, Lotton C et al (1994) Nucleosome-restricted antibodies are detected before anti-dsDNA and/or antihistone antibodies in serum of MRL-Mp lpr/lpr and +/+ mice, and are present in kidney eluates of lupus mice with proteinuria. Arthritis Rheum 37:1684–1688PubMedCrossRefGoogle Scholar
  16. 16.
    Ng KP, Manson JJ, Rahman A, Isenberg DA (2006) Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 55:900–904PubMedCrossRefGoogle Scholar
  17. 17.
    do Nascimento AP, Viana VST, Testagrossa LA, Leon EP et al (2006) Antibodies to ribosomal P proteins: a potential serologic marker for lupus membranous glomerulonephritis. Arthritis Rheum 54:1568–1572PubMedCrossRefGoogle Scholar
  18. 18.
    Waldman M, Madaio MP (2005) Pathogenic autoantibodies in lupus nephritis. Lupus 14:19–24PubMedCrossRefGoogle Scholar
  19. 19.
    Ravirajan CT, Rowse L, Macgowan JR, Isenberg DA (2001) An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus: a cross-sectional study. Rheumatology 40:1405–1412PubMedCrossRefGoogle Scholar
  20. 20.
    Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedCrossRefGoogle Scholar
  21. 21.
    Weening JJ, D’Agati VD, Schwartz MM, Seshan SV et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65:521–530PubMedCrossRefGoogle Scholar
  22. 22.
    Bombardier C, Gladman DD, Urowitz MB, Caron D et al (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640PubMedCrossRefGoogle Scholar
  23. 23.
    Aarden LA, de Groot ER, Feltkamp TE (1975) Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann N Y Acad Sci 254:505–515PubMedCrossRefGoogle Scholar
  24. 24.
    Mannik M, Merrill CE, Stamps LD, Wener MH (2003) Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J Rheumatol 30:1495–1504PubMedGoogle Scholar
  25. 25.
    Amoura Z, Piette JC, Bach JF, Koutouzov S (1999) The key role of nucleosomes in lupus. Arthritis Rheum 42:833–843PubMedCrossRefGoogle Scholar
  26. 26.
    Tikly M, Gould T, Wadee AA, van der Westhuizen E, Mokgethwa BB (2007) Clinical and serological correlates of antinucleosome antibodies in South Africans with systemic lupus erythematosus. Clin Rheumatol 26:2121–2125PubMedCrossRefGoogle Scholar
  27. 27.
    Saisoong S, Eiam-Ong S, Hanvivatvong O (2006) Correlations between antinucleosome antibodies and anti-double-stranded DNA antibodies, C3, C4, and clinical activity in lupus patients. Clin Exp Rheumatol 24:51–58PubMedGoogle Scholar
  28. 28.
    Grootscholten C, van Bruggen MC, van der Pijl JW, de Jong EM et al (2003) Deposition of nucleosomal antigens (histones and DNA) in the epidermal basement membrane in human lupus nephritis. Arthritis Rheum 48:1355–1362PubMedCrossRefGoogle Scholar
  29. 29.
    Ghillani-Dalbin P, Amoura Z, Cacoub P, Charuel JL et al (2003) Testing for anti-nucleosome antibodies in daily practice: a monocentric evaluation in 1696 patients. Lupus 12:833–837PubMedCrossRefGoogle Scholar
  30. 30.
    Stinton LM, Barr SG, Tibbles LA, Yimaz S et al (2007) Autoantibodies in lupus nephritis patients requiring renal transplantation. Lupus 15:394–400CrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2008

Authors and Affiliations

  • J. F. Carvalho
    • 1
  • V. S. T. Viana
    • 1
  • E. F. Borba
    • 1
  • A. P. do Nascimento
    • 1
  • E. P. Leon
    • 1
  • L. A. Testagrossa
    • 2
  • R. T. Barros
    • 3
  • E. Bonfá
    • 1
  1. 1.Disciplina de ReumatologiaFaculdade de Medicina da Universidade de São PauloSão PauloBrazil
  2. 2.Pathology DepartmentFaculdade de Medicina da Universidade de São PauloSão PauloBrazil
  3. 3.Nephrology DivisionFaculdade de Medicina da Universidade de São PauloSão PauloBrazil

Personalised recommendations